0.5 ML respiratory syncytial virus pre-fusion F protein, A, recombinant, stabilized 0.12 MG/ML / respiratory syncytial virus pre-fusion F protein, B, recombinant, stabilized 0.12 MG/ML Injection
SCD
14
These highlights do not include all the information needed to use ABRYSVO safely and effectively. See full prescribing information for ABRYSVO. ABRYSVO ® (Respiratory Syncytial Virus Vaccine) for injection, for intramuscular use Initial U.S. Approval: 2023
respiratory syncytial virus pre-fusion F protein, A, recombinant, stabilized 60 MCG / respiratory syncytial virus pre-fusion F protein, B, recombinant, stabilized 60 MCG per 0.5 ML Injection
SY
14
These highlights do not include all the information needed to use ABRYSVO safely and effectively. See full prescribing information for ABRYSVO. ABRYSVO ® (Respiratory Syncytial Virus Vaccine) for injection, for intramuscular use Initial U.S. Approval: 2023
respiratory syncytial virus pre-fusion F protein, A, recombinant, stabilized 60 MCG / respiratory syncytial virus pre-fusion F protein, B, recombinant, stabilized 60 MCG in 0.5 ML Injection
PSN
14
These highlights do not include all the information needed to use ABRYSVO safely and effectively. See full prescribing information for ABRYSVO. ABRYSVO ® (Respiratory Syncytial Virus Vaccine) for injection, for intramuscular use Initial U.S. Approval: 2023